Nalaganje...
Efficacy and Safety of Bcl-2 Inhibitor Venetoclax in Hematological Malignancy: A Systematic Review and Meta-Analysis of Clinical Trials
Background: B-cell leukemia/lymphoma-2 (BCL-2) protein is an important part of apoptotic pathway, which is overexpressed in chronic lymphocytic leukemia cells, non-Hodgkin lymphoma cells, and myeloma cells. Venetoclax (ABT-199/GDC-0199) is a highly selective bioavailable inhibitor of BCL-2 protein,...
Shranjeno v:
| izdano v: | Front Pharmacol |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Frontiers Media S.A.
2019
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6598635/ https://ncbi.nlm.nih.gov/pubmed/31293422 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2019.00697 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|